Lantern Pharma, LP-300, HARMONIC Trial, NSCLC, Non-Small Cell Lung Cancer, EGFR Mutation, L858R Mutation, Precision Oncology, Phase 2 Clinical Trial, Taiwan FDA, Clinical Trial Enrollment

DALLAS — October 7, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, announced regulatory and institutional...